Critical considerations for companies developing NASH drugs
Peter Traber focuses on ways COVID-19 can affect drug development and broader corporate strategies while our panelists weigh in on implications for clinical researchers, investors and forecasters in our third episode: C-SUITE COVID-19 CHALLENGES.
Browse Our NASH and COVID-19 Coverage https://surfingnash.com/covid-19/
